Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease

Respiration

Volumn 80, Issue 6, 2010, Pages 445-452

  He, Zhi Yi ^a   Ou, Li Mei ^b   Zhang, Jian Quan ^a   Bai, Jing ^a   Liu, Guang Nan ^a   Li, Mei Hua ^a   Deng, Jing Min ^a   MacNee, William ^c   Zhong, Xiao Ning ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b Hospital of Guangxi Zhuang Autonomous Region   (China)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Airway inflammation; Anti inflammatory effects; Chronic obstructive pulmonary disease; Exacerbation respiratory; Macrolides; Neutrophils

Indexed keywords

ERYTHROMYCIN; LEUKOCYTE ELASTASE; PLACEBO;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; INFLAMMATORY CELL; KAPLAN MEIER METHOD; MALE; MORAXELLA CATARRHALIS; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SPUTUM; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; VOMITING;

AGED; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; ERYTHROMYCIN; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SPUTUM; TREATMENT OUTCOME;

EID: 78649317470     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321374     Document Type: Article

References (39)

1. van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: a chronic systemic in-flammatory disease. Respiration 2008; 75: 224-238.
2. Pauwels RA, Rabe KF: Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364:613-620.
3. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
4. Calverley PM, Walker P: Chronic obstruc-tive pulmonary disease. Lancet 2003; 362: 1053-1061.
5. Saraiva-Romanholo BM, Barnabé V, Car-valho AL, Martins MA, Saldiva PH, Nunes Mdo P: Comparison of three methods for differential cell count in induced sputum. Chest 2003; 124:1060-1066.
6. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, Maestrelli P: Air-ways obstruction, chronic expectoration, and rapid decline of FEV 1 in smokers are as-sociated with increased levels of sputum neutrophils. Thorax 1996; 51: 267-271.
7. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, et al: Granulocyte inflamma-tory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349-355.
8. Ronchi MC, Piragino C, Rosi E, Amendola M, Duranti R, Scano G: Role of sputum dif-ferential cell count in detecting airway in-flammation in patients with chronic bron-chial asthma or COPD. Thorax 1996; 51: 1000-1004.
9. Keatings VM, Barnes PJ: Granulocyte acti-vation markers in induced sputum: compar-ison between chronic obstructive pulmo-nary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-453.
10. Barnes PJ: Emerging pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.
11. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with mod-erate to severe chronic obstructive pulmo-nary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303.
12. Crosbie PA, Woodhead MA: Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009; 33:171-181.
13. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A: Long-term low-dose administration of erythromycin to pa-tients with diffuse panbronchiolitis. Respi-ration 1991; 58: 145-149.
14. Keicho N, Kudoh S: Diffuse panbronchiol-itis: role of macrolides in therapy. Am J Respir Med 2002; 1:119-131.
15. Azuma A, Kudoh S: Diffuse panbronchiolitis in East Asia. Respirology 2006; 11:249-261.
16. King P: Is there a role for inhaled corticoste-roids and macrolide therapy in bronchiecta-sis? Drugs 2007; 67: 965-974.
17. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG: Clarithromycin targets neutro-philic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148-155.
18. Hahn DL: Macrolide therapy in asthma: lim-ited treatment, long-term improvement. Eur Respir J 2009; 33:1239.
19. Giamarellos-Bourboulis EJ: Macrolides be-yond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimi-crob Agents 2008; 31:12-20.
20. Gotfried MH: Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125:52S-60S.
21. Rubin BK, Henke MO: Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004; 125:70S-78S.
22. Tamaoki J: The effects of macrolides on in-flammatory cells. Chest 2004; 125:41S-50S.
23. Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al: Azithromycin modulates neutrophil function and circulat-ing inflammatory mediators in healthy hu-man subjects. Eur J Pharmacol 2002; 450: 277-289.
24. Oishi K Sonoda F, Kobayashi S, Iwagaki A, Nagatake T, Matsushima K, et al: Role of in-terleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. In-fect Immun 1994; 62: 4145-4152.
25. He Z, Li B, Yu L, Liu Q, Zhong N, Ran P: Sup-pression of oxidant-induced glutathione synthesis by erythromycin in human bron-chial epithelial cells. Respiration 2008; 75: 202-209.
26. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, et al: Erythro-mycin suppresses nuclear factor-?B and ac-tivator protein-1 activation in human bron-chial epithelial cells. Biochem Biophys Res Commun 2000; 267: 124-128.
27. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al: Global strategy for the diagnosis, management, and preven-tion of chronic obstructive pulmonary dis-ease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
28. Jones PW, Quirk FH, Baveystock CM, Little-johns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
29. SantAnna CA, Stelmach R, Zanetti Feltrin MI, Filho WJ, Chiba T, Cukier A: Evaluation of health-related quality of life in low-in-come patients with COPD receiving long-term oxygen therapy. Chest 2003; 123: 136-141.
30. Seemungal TA, Wilkinson TM, Hurst JR Perera WR, Sapsford RJ, Wedzicha JA: Long-term erythromycin therapy is associated with decreased chronic obstructive pulmo-nary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139-1147.
31. Yamaryo T, Oishi K, Yoshimine H, Tsuchi-hashi Y, Matsushima K, Nagatake T: Four-teen-member macrolides promote the phos-phatidylserine receptor-dependent phago-cytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemoth-er 2003; 47:48-53.
32. Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN: Azithromycin in-creases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006; 28:486-495.
33. Suzuki T, Yanai M, Yamaya M, Satoh-Na-kagawa T, Sekizawa K, Ishida S, et al: Eryth-romycin and common cold in COPD. Chest 2001; 120:730-733.
34. Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, Ilgazli A: The effect of clarithro-mycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 2004; 38:1400-1405.
35. Banerjee D, Khair OA, Honeybourne D: The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 2005; 99: 208-215.
36. Banerjee D, Honeybourne D, Khair OA: The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 2004; 3: 59-65.
37. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al: Microbiologic determinants of exacerbation in chronic obstructive pul-monary disease. Arch Intern Med 2005; 165: 891-897.
38. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Re-lationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
39. Sethi S, Murphy TF: Infection in the patho-genesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.